Format

Send to

Choose Destination
PLoS Biol. 2014 Jan;12(1):e1001758. doi: 10.1371/journal.pbio.1001758. Epub 2014 Jan 7.

Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth.

Author information

1
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America ; Microbiology Graduate Program, Yale University School of Medicine, New Haven, Connecticut, United States of America.
2
Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, United States of America.
3
Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, United States of America ; Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, United States of America.
4
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America.

Abstract

Type III interferon (IFN-λ) exhibits potent antiviral activity similar to IFN-α/β, but in contrast to the ubiquitous expression of the IFN-α/β receptor, the IFN-λ receptor is restricted to cells of epithelial origin. Despite the importance of IFN-λ in tissue-specific antiviral immunity, the molecular mechanisms responsible for this confined receptor expression remain elusive. Here, we demonstrate that the histone deacetylase (HDAC) repression machinery mediates transcriptional silencing of the unique IFN-λ receptor subunit (IFNLR1) in a cell-type-specific manner. Importantly, HDAC inhibitors elevate receptor expression and restore sensitivity to IFN-λ in previously nonresponsive cells, thereby enhancing protection against viral pathogens. In addition, blocking HDAC activity renders nonresponsive cell types susceptible to the pro-apoptotic activity of IFN-λ, revealing the combination of HDAC inhibitors and IFN-λ to be a potential antitumor strategy. These results demonstrate that the type III IFN response may be therapeutically harnessed by epigenetic rewiring of the IFN-λ receptor expression program.

PMID:
24409098
PMCID:
PMC3883642
DOI:
10.1371/journal.pbio.1001758
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

The authors have declared that no competing interests exist.

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center